Halpern Naama (Naama Halpern)

Years Active: 2017-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Halpern Naama, Ben Boursi, Einat Shacham-Shmueli, Einav Nili Gal-Yam, Ofer Margalit, Talia Golan, Tamar Beller, Gal Strauss, Dafna Yahav, Eyal Leshem
Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer. Oncology and therapy (2023)
Strauss Gal, Markovits Noa, Margalit Ofer, Halpern Naama, Boursi Ben, Shacham-Shmueli Einat
Oxaliplatin immune-mediated thrombocytopenia: Is there a role for premedication or desensitization? British journal of clinical pharmacology (2021)
Halpern Naama, Albert Grinshpun, Ben Boursi, Talia Golan, Ofer Margalit, Dan Aderka, Eitan Friedman, Yael Laitman, Ayala Hubert, Luna Kadouri, Tamar Hamburger, Inbal Barnes-Kedar, Zohar Levi, Irit Ben-Aharon, Baruch Brenner, Yael Goldberg, Tamar Peretz, Einat Shacham-Shmueli
Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review. OncoTargets and therapy 13 (2020)
Halpern Naama, Amir Sonnenblick, Beatrice Uziely, Luba Divinsky, Yael Goldberg, Tamar Hamburger, Tamar Peretz, Luna Kadouri
Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. International journal of cancer 140 (9) (2017)

Halpern Naama.css-eqlu8i{font-size:small;padding-left:4px;} (Naama Halpern)